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Background
The present work evaluates the cross-reactivity of com-
mercially available cyclic nucleotide analogs with cAMP-
and cGMP-immunoassays from Cayman, IBL (both IBL
International, Hamburg, Germany) and ENZO Life
Sciences (Loerrach, Germany).
Results and conclusion
Most of the tested cyclic nucleotide analogs showed low
degree competition with the antibodies; however, with
Rp-cAMPS, 8-Br-cGMP and 8-pCPT-cGMP a strong
cross-reactivity with the ENZO cAMP- respectively
cGMP-EIA and the IBL cGMP-RIA was observed (Table
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Table 1 Lipophilicity (log Kw), cell permeability and EIA/RIA specificity of selected cyclic Nucleotide analogs.
Analog Log
Kw
Permeability Specificity ENZO
cAMP-EIA
Specificity ENZO
cAMP-EIA
Specificity IBL
cGMP-RIA
Specificity Cayman
cGMP-EIA
2’-dcGMP 0.65 0% 5.21%
cGMP 0.77 100% 100% 100%
Rp-cGMPS 0.89 0.27% 10.6%
2’-dcAMP 0% 2.4%
cAMP 1.09 100%
8-Br-cGMP 1.17 12.1% 490% 20% 0.5%
Rp-cAMPS 1.21 12.2% 68%
8-Br-cAMP 1.35 8.0% 0.4%
Rp-8-Br-cAMPS 1.47 0.3%
6-MB-cAMP 1.64 0.4%
6-Bnz-cAMP 1.9 0.6%
8-pCPT-cGMP 2.52 19.6% 240% 30% 0.008%
8-pCPT-cAMP 2.65 22.0% 0.05%
8-Br-PET-cGMP 2.83 30.9% 10% 0.15% 1.6%
Rp-8-Br-PET-cGMPS 2.83 0.2%
8-pCPT-2’-OMe-cAMP (Epac
Activator)
2.94 0.03% 0.02%
Sp-5,6-DCI-cBIMPS 2.99 <0.001%
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any medium, provided the original work is properly cited.1). As a consequence we tested these derivatives with
the Cayman cGMP-EIA. This a s s a yi sl e s ss e n s i t i v et o
cGMP (1.0 pmol/ml) than the ENZO cGMP-EIA (0.01
pmol/ml), however the specificity concerning cGMP-
analogs is superior and therefore advantageous when
measuring cGMP in the presence of 8-Br-cGMP or 8-
pCPT-cGMP.
The determined EIA binding constants enabled the
measurement of the intracellular cyclic nucleotide con-
centrations and revealed a time- and lipophilicity-depen-
dent cell membrane permeability of the compounds in
the range of 10-30 % of the extracellular applied con-
centration after 20 min (Table 1).
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